Board of Directors
Mr. Chinitz co-founded Population Bio and has over 20 years of experience globally introducing new and leading edge technology to the research, pharmaceutical and diagnostic communities. He has held various positions on pioneering commercial teams within the life science industry leaders Hoffmann-La Roche, Applied Biosystems ["ABI"] (acquired by Thermo Fisher Scientific), Affymetrix, Third Wave Technologies (acquired by Hologic) and Enzo Life Sciences, including director and executive management level positions. He has broad-based expertise in sales, marketing, and business development and was intimately involved with the pioneering product launches of DNA sequencing, PCR, gene expression and genotyping technologies that were integral tools adopted for the Human Genome Project and today are the mainstream tools and methods used for human disease research. His role in the worldwide market adoption of DNA sequencing and microarrays has inspired Mr. Chinitz's vision for the acceleration of genetic discoveries and their clinical translation. Mr. Chinitz's BS degree is in Biochemical Pharmacology from SUNY Buffalo's School of Pharmacy and he attended business school through the University of California, Berkeley Extension.
Dr. Hatchwell co-founded Population Bio and manages the scientific operations at our UK site. He has engaged in genetic research for 25 years including as an Investigator at Cold Spring Harbor Laboratory and as an Associate Professor and Director of the Genomics Core Facility at SUNY at Stony Brook, where he maintains adjunct status. He is a certified Medical Geneticist (UK) with many years of experience in clinical practice. Dr. Hatchwell's clinical and technical expertise in investigating human genetic disorders led him to recognize early on that human genetic diversity was grossly underestimated, there was a critical need to comprehensively understand the vast spectrum of normal genetic variation in the population and that rare variants are largely responsible for causing common disease – the underlying principles of the genetic biomarker discovery technology of Population Bio. He is recognized as a key contributor in the development of one of the first genome-wide BAC-based comparative genomic hybridization (CGH) microarray platforms and remains at the forefront of cytogenetic and genome analysis through early adoption of leading edge technologies. Dr. Hatchwell collaborates with human genetics researchers worldwide, is a coauthor on numerous peer-reviewed articles encompassing both clinical genetics and genome technologies, and is senior editor of a book series aimed at educating medical specialists on genetic principles and practices. Dr. Hatchwell received his medical degree from the University of Cambridge, his DPhil in Molecular Genetics from the University of Oxford, and was a Wellcome Advanced Clinical Training Fellow. He also holds a degree (BA) from the Open University (UK), with a strong emphasis on Mathematics.
Josiah C. Hornblower is a co-founder of Pelican Therapeutics and is its acting Chief Executive Officer. He is also a member of its Board of Directors. Josiah is a private investor focused on companies in biotechnology and financial services. He is a managing member of Aristar Ventures III, the lead outside investor in Pelican Therapeutics, an immuno-oncology company. Since 2008, Josiah has been a Managing Member of Blue Pine Partners, LLC, an investment and advisory firm that he founded in the community bank sector. From 2004 to 2008, Josiah was a principal of Resource Financial Institutions Group, Inc. (RFIG), a manager of private equity funds solely devoted to investing in early stage commercial banks. During that period, he served on the Board of Directors of Pacific Enterprise Bancorp, an Orange County, California-based commercial bank. Before joining RFIG, Josiah worked as an equity analyst at Gray Seifert and Co., an investment management firm specializing in financial services, and at Barrett Associates, Inc. At both firms, he researched and invested in regional banks and financial technology companies. Josiah is currently a director of Capital Pacific Bank, based in Portland, Oregon. Josiah graduated with a Bachelor of Arts degree from Trinity College and was a member of Phi Beta Kappa. He resides in Austin, Texas.
Ed Smith is the Managing Partner of Aristar Capital Management, LLC, a New York-based investment firm that is the lead investor in PB. In January 2015, Mr. Smith was appointed Chief Executive Officer of Z Trim Holdings Inc. (OTC:ZTHO), an agricultural biotechnology company that has developed new products and processes to transform biomass for uses in the food and industrial markets. From April 2005 through December 2014, Mr. Smith was a Managing Partner of Brightline Capital Management, LLC ("BCM"), a New York-based investment firm founded in 2005. Prior to founding BCM, Mr. Smith worked at Gracie Capital from 2004-2005, GTCR Golder Rauner from 1999-2001 and Credit Suisse First Boston from 1997-1999. Mr. Smith holds a Bachelor of Arts in Social Studies from Harvard College and a Masters in Business Administration from Harvard Business School. Mr. Smith is also a director of Z Trim Holdings, Inc., Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company focused on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases, and Pelican Therapeutics, an immuno-oncology company.